Compare SAMG & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | CLNN |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 85.7M |
| IPO Year | 2012 | N/A |
| Metric | SAMG | CLNN |
|---|---|---|
| Price | $10.79 | $5.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 36.2K | ★ 96.5K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | $363.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.68 | $3.25 |
| 52 Week High | $16.97 | $13.50 |
| Indicator | SAMG | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 32.03 | 43.55 |
| Support Level | $10.68 | $5.46 |
| Resistance Level | $11.66 | $6.92 |
| Average True Range (ATR) | 0.36 | 0.37 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 26.79 | 29.53 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.